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95% CI 2.59 (1.70–3.93), p < 0.001], respectively. AST values 
above normal were associated with fibrosis (63 vs. 40% for 
normal AST, p = 0.010). Elevated ferritin levels pointed to a 
higher incidence of steatosis (48 vs. 10% for normal ferritin, 
p < 0.001) and inflammation (87 vs. 62% for normal ferritin, 
p = 0.004).  Conclusions: Our results indicate that elevated 
AST and GLDH were associated with a greater likelihood of 
recommending liver biopsy. Elevated AST and ferritin levels 
were associated with steatosis, inflammation and fibrosis on 
liver biopsies. Thus, AST and ferritin may be useful non-inva-
sive predictors of liver pathology in patients with unclear 
hepatopathy.  © 2014 S. Karger AG, Basel 
 Introduction 
 Liver enzymes and cholestasis parameters are widely 
used for screening and monitoring hepatobiliary disor-
ders. Elevated liver enzymes are rather common, at least 
in Western countries. It has been suggested that 10–25% 
of German adults have increased alanine aminotransfer-
ase (ALT) levels  [1] . An abnormal liver chemistry has 
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 Abstract 
 Background and Aims: Despite increasingly sensitive and 
accurate blood tests to detect liver disease, liver biopsy re-
mains very useful in patients with atypical clinical features 
and abnormal liver tests of unknown etiology. The aim was 
to determine those elevated laboratory liver parameters that 
cause the clinician to order a biopsy, and whether laboratory 
tests are associated with pathological findings on histology. 
 Methods: 504 patients with unclear hepatopathy, admitted 
to the outpatient clinic of a university hospital between 2007 
and 2010, were analyzed with respect to laboratory results, 
clinical data, and the results of liver biopsies.  Results: Aspar-
tate aminotransferase (AST) and glutamate dehydrogenase 
(GLDH) levels above the normal range significantly increased 
the likelihood of recommending a liver biopsy by 81% [OR 
with 95% CI 1.81 (1.21–2.71), p = 0.004] and 159% [OR with 
 Received: January 17, 2014 
 Accepted: March 21, 2014 
 Published online: July 25, 2014 
 Johannes Wilhelm Rey, MD 
 St. Mary’s Hospital Frankfurt 
 Richard-Wagner-Strasse 14 
 DE–60318 Frankfurt (Germany) 
 E-Mail johannes.wilhelm.rey   @   t-online.de 
 © 2014 S. Karger AG, Basel
0012–2823/14/0894–0310$39.50/0 
 www.karger.com/dig 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
, R
eg
en
sb
ur
g
13
2.
19
9.
14
5.
19
5 
- 1
0/
7/
20
19
 3
:2
4:
21
 P
M
 Liver Biopsy in Unclear Hepatopathy Digestion 2014;89:310–318
DOI: 10.1159/000362404
311
been reported in 1–4% of asymptomatic individuals and 
is commonly discovered incidentally in routine labora-
tory testing  [2] . The dilemma of testing for ALT is that 
elevated ALT levels have been identified in patients with-
out liver disorders  [3] , but increased liver enzymes were 
also closely linked with liver disease and pathological 
changes in liver tissue.
 One of the most common diagnoses in patients with 
abnormal ALT values is fatty liver disease  [4] . A popula-
tion-based survey in the United States showed abnormal 
ALT values in 8.9% of persons; this may be related to the 
greater prevalence of obesity in the last few years  [5] . ALT 
levels were shown to correlate with the body mass index 
(BMI), increasing significantly over time  [6] . However, 
the latter study contained many patients (45%) whose el-
evations remained unexplained. ALT was increased in the 
majority of, but not all, German patients with acute and 
chronic liver disease  [1] . It may even be of predictive val-
ue for survival. Screening for elevated liver enzyme activ-
ity in a large German cohort of construction workers 
demonstrated a strong relationship between elevated liv-
er parameters, early retirement, and mortality  [7, 8] . Fur-
thermore, elevated serum levels of aspartate aminotrans-
ferase (AST) and ALT registered in routine medical care 
were reported to be associated with future mortality in 
community residents  [9] .
 Liver biopsy is a diagnostic gold standard, and is per-
formed to establish a precise diagnosis in patients with 
long-term elevations in liver parameters. However, a liver 
biopsy involves the risk of bleeding, perforation, and in-
fection  [10] . Given the low prevalence of clinically sig-
nificant liver disease – a mere 1% of patients – and the 
limited value of blood tests for distinguishing between 
patients with severe and those with benign liver disease, 
more precise prediction of the need for liver biopsy would 
be a significant step forward in the diagnostic algorithm 
of liver disease. A liver biopsy is considered mandatory to 
establish the diagnosis in asymptomatic patients with el-
evated ALT levels  [11] . Nevertheless, a rational approach 
to liver biopsy is most urgently needed  [12] .
 Independent of published recommendations, the deci-
sion to perform a liver biopsy is a major diagnostic step. 
In a prospective investigation of patients with abnormal 
serum aminotransferase levels, liver biopsies revealed ste-
atosis or steatohepatitis in 84%. An initial dietary treat-
ment approach was used in these patients, resulting in 
considerable weight loss. It proved to be an effective treat-
ment in many patients and obviated the need for liver 
biopsy  [13] . In a further study comprising 36 patients 
with chronic elevations of serum ALT, AST or alkaline 
phosphatase (AP) levels, the liver biopsy changed the di-
agnosis in just 5 individuals, and influenced the treatment 
in 12 patients. The authors concluded that the risks and 
benefits of liver biopsy should be weighed carefully, espe-
cially when investigational therapies are not available 
 [14] . Hay et al.  [15] described 47 patients with chronic 
elevated aminotransferase levels, who underwent full 
evaluation and liver biopsies. The patients had no clinical 
symptoms of liver disease. Steatohepatitis was diagnosed 
in 10 patients while chronic hepatitis was established in 
34, of whom 16 had evidence of cirrhosis on biopsy and 
3 had miscellaneous diagnoses. Nonetheless, in some cas-
es liver biopsy provides meager additional information, 
such as in patients with mild fibrosis  [16] . It has also been 
mentioned that patients with elevated liver enzymes may 
have a normal liver histology  [17] .
 Liver biopsy and histological assessment of the liver 
remains an important diagnostic tool in clinical manage-
ment. The current AASLD recommendations for liver bi-
opsy mention three major categories: (a) for diagnosis, 
(b) for the assessment of prognosis (disease staging), and/
or (c) to assist in making therapeutic decisions  [18] .
 To determine suitable candidates for liver biopsy, we 
evaluated the impact of abnormal liver chemistry on the 
decision to perform liver biopsies. This was a retrospec-
tive single-center assessment of patients who presented at 
our outpatient hepatology department.
 Methods 
 Patient Cohort 
 Patients with a medical history of unclear hepatopathy and 
negative tests for viral hepatitis A, B, or C, referred by general prac-
titioners and treated at the outpatient hepatology department of 
the University Medical Center of Mainz between 2007 and 2010, 
were analyzed retrospectively. Of 504 patients, 240 (47.6%) were 
male and 264 (52.4%) were female. Patients with known preexist-
ing hepatic conditions such as autoimmune hepatitis, primary bil-
iary cirrhosis, primary sclerosing cholangitis, frequent alcohol 
consumption, or liver cirrhosis were excluded. Patients with a pos-
itive CMV test were also excluded. Data were obtained from pa-
tient files in the SAP TM hospital information system, discharge 
summaries, history sheets, and ultrasound investigation. The pa-
tients’ BMI, laboratory values, date of birth, and gender were reg-
istered. Pathological data concerning steatosis, fibrosis, inflamma-
tion, and cirrhosis were taken from the medical files.
 Data Analysis 
 Microsoft Excel TM and SPSS 17 for Windows TM were used for 
data archiving and analysis. Patients who underwent liver bi-
opsy directly after initial presentation or within a 6-month pe-
riod when elevated liver enzymes did not improve were identi-
fied as those recommended to undergo a biopsy. All other pa-
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tients were considered to have received no recommendation for 
a biopsy. Laboratory data were classified as normal, reduced, or 
increased.
 Statistics 
 In univariate analyses we compared, for each parameter, the 
relative frequency of a recommendation to undergo a biopsy be-
tween patients within and out of the normal range of the param-
eter by performing χ 2 tests. The same type of analysis was per-
formed to compare relative frequencies of abnormal pathological 
findings between groups. For multivariate analyses we used mul-
 Table 1.  Suspected diagnoses leading to referral to a university hos-
pital outpatient clinic
Patients %
Unspecific hepatitis 3 0.6
Liver cirrhosis 1 0.2
NAFLD 90 17.9
Toxic hepatopathy 11 2.2
Unclear hepatopathy 399 79.2
 Table 2.  Summary of laboratory data
Acute-phase proteins C-reactive protein, ceruloplasmin, haptoglobin, transferrin
Antibodies Anti-gliadin antibodies, antimitochondrial antibodies, antimitochondrial antibodies-M2,
anti-cyclic citrullinated peptide antibody (IgG), centrally accentuated antineutrophil 
cytoplasmic antibody, perinuclear antineutrophil cytoplasmic antibody, antinuclear 
antibodies, anti-double-stranded DNA antibody, liver kidney microsomal antibodies, 
antibody against soluble liver antigen, smooth muscle antibody, immunoglobulin A, 
immunoglobulin D, immunoglobulin E, immunoglobulin G, immunoglobulin M, HIV 
antigen/antibody test, rheumatoid factor, nuclear deoxyribonucleic acid, myeloperoxidase 
antibody, parietal cell antibody, antiproteinase-3 antibody
Blood count Basophil granulocytes, polymorphonuclear leukocytes, band neutrophils, erythrocytes, red 
blood cell distribution width, hematocrit, hemoglobin, leukocytes, lymphocytes, 
thrombocytes, mean platelet volume, mean corpuscular hemoglobin, mean corpuscular 
volume, monocytes, neutrophilic leukocytes
Cholestasis parameters γ-Glutamyl transferase, alkaline phosphatase
Coagulation Fibrinogen, prothrombin time, partial thromboplastin time, D-dimer
Complement system C4
Copper metabolism Copper, ceruloplasmin
Electrolytes Calcium, chloride, potassium, magnesium, sodium
Electrophoresis α-Globulins, α2-globulins, α2-macroglobulin, β-globulin, γ-globulin
Enzymes Muscle-brain type creatinine kinase, creatinine kinase, glutamate dehydrogenase, lactate 
dehydrogenase
Excretory activity Bilirubin
Glycoproteins α1-Proteinase inhibitor
Hemochromatosis parameters Ferritin, iron, transferrin
Hepatitis serology Antihepatitis A IgG and IgM antibodies, surface antigen of the hepatitis B virus, antibody to 
the hepatitis B surface antigen, antibody against hepatitis C virus, antibody to hepatitis B core 
antigen
Infectiology Anticytomegalovirus antibodies, IgG and IgM
Liver function parameters Albumin, cholinesterase, prothrombin time
Metabolism of lipids Apolipoprotein A1, apolipoprotein B, cholesterol, high-density lipoprotein cholesterol,
low-density lipoprotein cholesterol, HDL/LDL quotient, triglycerides
Other Glucose, phosphate
Pancreatic function parameters α-Amylase, lipase
Proteins, metabolites Total protein, uric acid, urea
Renal function parameters Creatinine
Thyroid parameters Free thyroxine, thyroid-stimulating hormone, triiodothyronine, antithyroid peroxidase 
antibodies, antithyroglobulin antibodies
Transaminases Aspartate aminotransferase, alanine aminotransferase
Tumor markers α1-Fetoprotein, carbohydrate antigen 19-9
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tiple logistic regressions to identify those variables that made the 
most important contribution to the recommendation for a liver 
biopsy. Hosmer-Lemeshow test statistics and the area under the 
receiver operating curve were used to determine the quality of 
model fitting and discrimination, respectively. As this was an ex-
ploratory study, all analyses were considered exploratory; p values 
were only given for descriptive reasons.
 Results 
 Laboratory Data in a Large Cohort of Hepatitis A-, B-, 
or C-Negative Patients with Elevated ‘Liver Enzymes’ 
 We analyzed, in a retrospective single-center study, 
504 patients who attended our hepatology outpatient 
center; 240 patients (47.6%) were male and 264 (52.4%) 
were female. Unclear hepatopathy was suspected on clin-
ical investigation in 399 patients (79.2%) prior to their 
admission to the hospital. Non-alcoholic fatty liver dis-
ease (NAFLD) was suspected in 90 patients (17.9%) ( ta-
ble 1 ). The patients’ medical records revealed 149 regis-
tered laboratory parameters ( table 2 ). Excluding unavail-
able patient records, laboratory values were evaluated for 
473 patients. In addition to BMI and age, nine liver labo-
ratory parameters known to be indicators of liver func-
tion were selected ( table 3 a). Median values of AP, biliru-
bin and ferritin were in the normal range. In contrast, 
glutamate dehydrogenase (GLDH), AST, ALT, γ-glutamyl 
transferase (γ-GT), prothrombin time and platelet agents 
were above the upper limit of normal. The patients’ me-
dian BMI was 27 (min. 18, max. 44) and their median age 
48 years (min. 15 years, max. 87 years). Abnormal meta-
bolic values were seen in 24.5–32.3% of patients ( ta-
ble 3 b).
 Ultrasound of the Liver 
 421 (83.5%) patients underwent ultrasound investiga-
tion of the liver. Hepatic steatosis was suspected in 262 
(62.3%) and cirrhosis in 10 patients (2.4%); 78 patients 
(18.5%) had no pathological findings on ultrasound. 
Doppler ultrasound findings were not evaluated.
 Single Liver Enzymes and the Indication for Liver 
Biopsy 
 Among the selected blood parameters, median val-
ues of ALT, AST, γ-GT, GLDH, prothrombin time, and 
platelet agents were above normal ( table 3 a). These and 
three additional variables were analyzed with regard to 
their role in the decision to perform a liver biopsy.  Ta-
ble 4 summarizes univariate analyses of the association 
among these variables and the recommendation for bi-
opsy. Transaminases, GLDH and ferritin differed sig-
nificantly in their contribution to the recommendation 
to perform a liver biopsy when the respective values 
were above the normal range. Specifically, above-nor-
mal GLDH levels influenced the recommendation to 
undergo a liver biopsy in 61% of cases, compared to 
33% in patients with normal GLDH levels. For multi-
variate analysis, thrombocytes, AP, GLDH, AST, ALT, 
γ-GT, bilirubin, prothrombin time, ferritin and gender 
were analyzed with respect to their impact on perform-
ing a biopsy. All other parameters [BMI, ultrasound, 
cholesterol, albumin, cholinesterases, lactodehydroge-
nase (LDH)] were excluded because of the large num-
ber of missing values and because univariate analyses 
indicated their minimal impact on the decision to per-
form a biopsy. Forward and backward stepwise logistic 
regression using a likelihood ratio p value of  ≤ 5% and 
>10% as variable inclusion and exclusion criterion, re-
spectively, both identified an AST value above the nor-
 Table 3. Descriptive values of laboratory tests, age and BMI, se-
lected for analysis, (a) and metabolic values (b) 
a
Values, 
n
Mini-
mum
Median Maxi-
mum
BMI 346 18 27 44
Age, years 504 15 48 87
AP, U/l 493 30 84 701
GLDH, U/l 473 1.4 9.65 314.9
AST, U/l 500 17 39 1,290
ALT, U/l 499 13 68 1,283
Bilirubin, mg/dl 491 0.17 0.6 13.59
γ-GT, U/l 494 9 95 1,631
Ferritin, ng/ml 440 4 116 4,503
Prothrombin time, /s 490 16 104 127
Thrombocytes, /nl 498 54.00 285 631.00
b
Variable Normal range n (%)
HDL >40
≤40
327 (73.2)
120 (26.8)
LDL <160
≥160
320 (75.5)
104 (24.5)
Cholesterol <200
≥200
306 (67.7)
146 (32.3)
Triglycerides <200
≥200
327 (72.3)
125 (27.7)
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mal range (>35 U/l) and a GLDH value above the nor-
mal range (>7 U/l) as those variables that contributed 
markedly to the recommendation to perform a liver bi-
opsy. A final model including only these two factors as 
independent variables was fitted to account for missing 
values in non-selected variables. The final model, based 
on the data of 473 patients, indicated that AST levels 
above the normal range increased the risk by 81% [OR 
with 95% CI 1.81 (1.21–2.71), p = 0.004] and a GLDH 
above the normal range increased the risk of recom-
mending a liver biopsy by 159% [OR with 95% CI 2.59 
(1.70–3.93), p < 0.001]. Model fit was rated well accord-
ing to a Hosmer-Lemeshow test statistic of χ 2 = 0.01
(p = 0.995), whereas discrimination was only moderate, 
with an area under the receiver operating curve of 0.661 
( table 5 ).
 Liver Biopsy 
 In 201 patients (39.9%), liver biopsy was recommend-
ed immediately after the clinical consultation of a hepa-
tologist at our outpatient center. 162 patients (32.1%) un-
derwent a liver biopsy after their first consultation. These 
patients had various stages of steatosis, inflammation, or 
 Table 4.  Fifteen laboratory and clinical parameters and their influence on the decision to perform a liver biopsy
Variable Values, n Normal
range
All patients,
n 
Number (%) of patients
with recommendation 
for a biopsy
p value
(χ2 test)
AP, U/l 493 ≤130
>130
413
80
200 (48)
48 (60)
0.076
GLDH, U/l 473 ≤7
>7
169
304
55 (33)
184 (61)
<0.001
AST, U/l 500 ≤35
>35
208
292
79 (38)
171 (59)
<0.001
ALT, U/l 499 ≤50
>50
146
353
51 (35)
199 (56)
<0.001
γ-GT, U/l 494 ≤60
>60
138
356
52 (38)
198 (56)
<0.001
Ferritin, ng/ml 440 ≤200
>200
289
151
131 (45)
88 (58)
0.013
Prothrombin time, % 490 ≥70
<70
470
20
239 (51)
9 (45)
0.776
Bilirubin, mg/dl 491 ≤1.2
>1.2
437
54
219 (50)
30 (56)
0.542
Thrombocytes, /nl 498 ≥150
<150
480
18
240 (50)
11 (61)
0.493
Gender 504 male:
female:
240
264
124 (52)
128 (49)
0.532
Albumin, g/l 450 ≥35
<35
434
16
223 (51)
7 (44)
0.73
Cholinesterases, kU/l 449 ≥5
<5
443
6
223 (50)
4 (67)
–
LDH, U/l 456 ≤250
>250
362
94
178 (49)
52 (55)
0.344
Cholesterol, mg/dl 452 ≤200
>200
148
304
75 (51)
153 (50)
0.975
Ultrasound 421 no
yes
78
343
39 (50)
175 (51)
0.97
 Table 5.  Logistic regression model with GLDH and AST as the in-
dependent variables associated with the recommendation to un-
dergo a biopsy (dependent variable) (n = 473)
Variable OR (95% CI) p (Wald test)
GLDH (>7 vs. ≤7) 2.59 (1.70 – 3.93) <0.001
AST (>35 vs. ≤35) 1.81 (1.21 – 2.71) 0.004
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fibrosis in 37.7, 68.5 and 54.3%, respectively. Cirrhosis 
was found in 11% of cases. Besides, 51 patients (10.1%) 
were advised to undergo a liver biopsy because their clin-
ical and laboratory values did not improve; 303 patients 
did not undergo a liver biopsy (60.1%).
 Laboratory Results and Pathological Findings on Liver 
Histology 
 For any histology result (steatosis, inflammation, fi-
brosis, cirrhosis) compared with one of five laboratory 
values (GLDH, AST, ALT, γ-GT and ferritin) that had a 
significant influence for a recommendation for liver bi-
opsy, no differences could be detected in the pathology 
result, neither in normal nor in values above the normal 
range ( table 6 ).
 Detailed histological results were compared to those pa-
rameters that contributed significantly to the recommen-
dation to undergo a biopsy. AST levels above the normal 
range (>35 U/l) were related to fibrosis on liver biopsy (63 
vs. 40%, p = 0.010). Ferritin values above normal were 
strongly associated with pathological results for steatosis 
(48 vs. 10%, p < 0.001) and inflammation (87 vs. 62%, p = 
0.004). Pathological data were found in 96% of patients 
whose ferritin was above normal, but only in 83% whose 
ferritin levels were normal (p = 0.066). The most common 
pathological findings in parameters that contributed sig-
nificantly to the recommendation to undergo liver biopsy 
were inflammation and fibrosis. Inflammation was detect-
ed in 67% of patients with elevated γ-GT and in 87% with 
elevated ferritin levels. Fibrosis was seen in 63% of patients 
with AST levels above normal and in 53% of patients with 
elevated GLDH. When γ-GT and GLDH were elevated, 
pathological data of any type were noted in 86% of patients.
 Discussion 
 Diagnostic evaluation of patients with unexplained 
liver pathologies still is a challenge for the gastroenterolo-
gist. The specificity of parameters used to determine liver 
disease is low. In clinical routine, patients with (margin-
ally) elevated liver enzymes frequently reveal no serious 
liver pathologies  [13] . In a recent study, NAFLD was re-
ported to be the most common diagnosis in patients with 
elevated liver enzymes  [19] . ALT was reported to corre-
late with BMI  [20] . Elevated liver enzymes were shown to 
be associated with higher mortality. Thus, patients with a 
serious liver condition must be identified promptly. 
About one fifth of our patients had abnormal metabolic 
values ( table 3 b), although the median BMI of all patients 
was 27. However, our data provide no confirmation of the 
thesis that obesity and elevated cholesterol levels influ-
enced the decision to perform a liver biopsy, although 
these parameters are hallmarks of NAFLD or NASH.
 Table 6.  Comparison of the results of liver biopsy between patients with and without normal values for GLDH, 
AST, ALT, γ-GT and ferritin
Variable Normal 
range
All patients,
n
Steatosis,
n (%)
Foci,
n (%)
Fibrosis,
n (%)
Cirrhosis,
n (%)
Any result,
n (%)
GLDH ≤7
>7
40
113
8 (20)
25 (22)
p = 0.955
30 (75)
77 (68)
p = 0.540
24 (60)
60 (53)
p = 0.569
6 (15)
12 (11)
p = 0.650
36 (90)
97 (86)
p = 0.691
AST ≤35
>35
53
107
9 (17)
26 (24)
p = 0.395
31 (59)
80 (75)
p = 0.055
21 (40)
67 (63)
p = 0.010
4 (8)
14 (13)
p = 0.437
42 (79)
97 (91)
p = 0.078
ALT ≤50
>50
37
123
6 (16)
29 (24)
p = 0.470
22 (69)
89 (72)
p = 0.197
18 (49)
70 (57)
p = 0.486
5 (14)
13 (11)
p = 0.841
30 (81)
109 (89)
p = 0.361
γ-GT ≤60
>60
32
128
10 (31)
25 (20)
p = 0.232
25 (78)
86 (67)
p = 0.324
17 (53)
71 (56)
p = 0.968
4 (13)
14 (11)
p = 0.950
29 (91)
110 (86)
p = 0.682
Ferritin ≤200
>200
89
47
9 (10)
21 (48)
p < 0.001
55 (62)
41 (87)
p = 0.004
50 (56)
29 (62)
p = 0.661
11 (12)
5 (11)
p = 0.987
74 (83)
45 (96)
p = 0.066
 p values were calculated using a χ2 test.
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 An ultrasound investigation was performed in 83.5% 
of patients. Hepatic steatosis was suspected in 62.3% and 
liver cirrhosis in a mere 2.4%. Of 162 patients who under-
went liver biopsy directly after the initial consultation, 
37.7% had hepatic steatosis on histopathological investi-
gation. This amounted to a lower prevalence of patho-
logical findings than reported previously  [21] . These dif-
ferences may be explained by the fact that liver biopsies 
are liberally recommended at our outpatient center. 
However, our results indicate that a substantial number 
of patients with unclear hepatopathy had steatosis in their 
liver biopsy specimens. Despite contrary reports, the 
most common histological findings in our study were in-
flammation and fibrosis  [21] . Thus, some patients with 
unclear hepatopathy appear to have been in advanced 
stages of liver damage at the time of biopsy. This high-
lights the importance of performing liver biopsy on a 
timely basis, especially with respect to its therapeutic con-
sequences  [18] . In our data, the most common patholog-
ical findings on liver chemistry were those of ALT, AST, 
γ-GT and GLDH. Bilirubin levels were normal.
 ALT is an unreliable parameter because it varies in re-
lation to gender, age, and other factors. It is also unreli-
able because of various reference standards used in labo-
ratories. Therefore, comparing values across laboratories 
may not be helpful  [22] . In our analysis, an increase in 
ALT did not affect the decision to perform liver biopsy 
alone. It has been suggested that ALT may be a better in-
dicator of liver disease because of its limited tissue distri-
bution. Mild disorders of liver homeostasis are associated 
with the release of cytoplasmic enzymes, whereas severe 
injury results in greater release of cytoplasmic and mito-
chondrial AST. Despite these considerations, our data 
suggest that a rise in AST and GLDH rather than ALT or 
γ-GT is crucial for the decision to perform a liver biopsy. 
However, GLDH has been rarely investigated as a marker 
in unclear hepatopathy. Some recently published data 
provided evidence of GLDH as a biomarker in the assess-
ment of patients with acetaminophen-induced liver in-
jury  [23] .
 Our results indicated that most patients who under-
went liver biopsy had at least one pathological value, in-
cluding those with no changes in AST, GLDH, or ferritin. 
It may be concluded that, notwithstanding the results of 
laboratory tests, liver biopsies should be performed liber-
ally. Based on our own liberal approach, we identified 
pathological findings in as many as 92% of patients. Nor-
mal transaminases were no valuable criterion to exclude 
patients from liver biopsy  [24] . In addition to laboratory 
data, the patient’s clinical symptoms, drug history and 
medical history should be given priority when deciding 
to perform a liver biopsy  [25–33] .
 We lack sufficient data to justify the use of non-inva-
sive diagnostic procedures alone in patients with ambig-
uous liver disease. However, although it is common prac-
tice to rely on ALT and GLDH (because these parameters 
have been significantly linked with liver biopsy), we 
showed that above-normal AST and ferritin levels may 
be of even greater predictive value in regard of the histo-
pathological result. In our patients, elevated ferritin lev-
els were significantly associated with steatosis and in-
flammation on histopathology than normal levels of fer-
ritin. Patients with elevated AST values had fibrosis 
significantly more often compared to patients with nor-
mal AST levels. It has been reported that above-normal 
ferritin values may be a predictor of advanced hepatic 
fibrosis in patients with NAFLD  [34] . Although histo-
logical evaluation of the liver has become important in 
assessing prognosis and tailoring treatment, non-inva-
sive techniques (such as imaging investigations or blood 
tests) may replace the use of liver histology in this setting, 
particularly for the assessment of the severity of liver fi-
brosis  [18] .
 Despite these findings, our data suggest that elevated 
ferritin values are predictive of inflammation and hepatic 
steatosis in liver-biopsied patients with unclear hepatop-
athy. However, other authors have reported no signifi-
cant difference in these parameters  [35] . This may be 
partly due to the different sizes of patient cohorts. Ours 
contained more than 500 patients and was larger than the 
majority of sample sizes investigated so far. Thus, ferritin 
might be of greater importance in decision-making for 
liver biopsy in patients with unclear hepatopathy.
 Multivariate analysis in our study showed that AST 
levels influenced the decision to perform a liver biopsy. 
AST levels above normal were predictive of fibrosis. A 
correlation between AST and liver fibrosis was previous-
ly studied as part of the AST-to-platelet ratio test (APRI). 
These data suggested the predictive value of liver fibrosis 
when the APRI test result rose to above 0.7. However, 
APRI was of limited use in the diagnosis of fibrosis in 
many patients  [36] .
 The American Gastroenterology Association (AGA) 
recommends liver biopsy as a useful prognostic and diag-
nostic test in patients with elevated serum liver chemistry 
for longer than 6 months. However, even with a high rate 
of patients undergoing immediate liver biopsy on the rec-
ommendation of an experienced hepatologist, we detect-
ed a high rate of pathological findings. Thus, the decision 
to perform a biopsy must be adjusted to the patient’s 
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symptoms, liver chemistry abnormalities, age, lifestyle, 
the desire for prognostic information, and associated co-
morbid conditions  [37] . According to previous reports, 
the principal value of biopsy tissue is to identify a pattern 
of injury from which diagnostic options may be consid-
ered, assessed, validated, or discarded  [38] . In contrast, 
the AASLD recommends a liver biopsy in patients with 
questionable diagnoses, and when knowledge of a spe-
cific diagnosis is likely to alter the management plan. Fur-
thermore, it has been suggested that liver histology is an 
important adjunct in the management of patients with 
known liver disease  [18] .
 Overall, our data clearly suggest the necessity and val-
ue of routine testing of liver enzymes, as well as empha-
size the need for further evaluation and a better under-
standing of these tests for clinical decision-making, espe-
cially with respect to liver biopsy. In the majority of cases, 
a change in lifestyle may be the appropriate recommen-
dation to improve liver enzymes. However, the diagnosis 
of liver inflammation or liver fibrosis may highlight the 
urgency to determine the underlying cause of a change in 
liver homeostasis and closer monitoring of liver disease 
to prevent life-limiting conditions.
 The limitations of the present study are worthy of men-
tion. First, not all virological parameters were available in 
order to exclude the patients from the study. Second, liver 
histology was performed percutaneously and by mini-lap-
aroscopy in the endoscopic unit. Sampling errors may have 
occurred in the procedures. Third, ultrasound findings are 
of limited value because they were evaluated retrospective-
ly and may have been influenced by the examiner. Finally, 
as the patients’ medical histories were not available, the 
influence of liver pathologies cannot be ruled out.
 In conclusion, this retrospective single-center study 
indicated that AST and GLDH values above the normal 
range had the greatest influence on the attending hepa-
tologist’s decision to perform a liver biopsy. However, el-
evated AST and ferritin levels varied markedly in terms 
of the severity of steatosis, inflammation, and fibrosis in 
liver biopsies of patients with abnormal liver tests of un-
known etiology.
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